drugset
drugset / Trial / NCT06573528

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects

NCT06573528 ↗

Phase 1 Completed 104 enrolled Cascade Pharmaceuticals, Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

Study to Evaluate Safety, Tolerability and Pharmacokinetics of CS060380 in Healthy and Elevated LDL-C Subjects.

Timeline

Start
2024-09-03
Primary completion
2025-05-09
Completion
2025-05-21

Drugs

EvaluationDrugModalityDoseRoute
Subject CS060380 Unknown 0.1 mg Oral
Subject CS060380 Unknown 0.15 mg Oral
Subject CS060380 Unknown 0.2 mg Oral
Subject CS060380 Unknown 0.25 mg Oral
Subject CS060380 Unknown 0.5 mg Oral
Subject CS060380 Unknown 0.75 mg Oral
Subject CS060380 Unknown 1 mg Oral
Subject CS060380 Unknown 2 mg Oral
Subject CS060380 Unknown 5 mg Oral
Subject CS060380 Unknown 10 mg Oral

Indications

No indication recorded.